completely agree. this stock has been heavily manipulated for at least 3 years. Negative P/E, 6 employees. No revenue. Analysts figure Firdlapse in US is worth $3-$4 by the end of 2016, so other than buyout speculation there's no reason for the shares to price above that right now. Manipulation on this one brought it almost to the high end of that range 2 yrs early, so it could just as easily manipulate back to sub $1 again before the next pump and run up.
always nice to see someone with a 'thumbs down' to the answer to a math question. polly asked about what Firdlapse is worth...that's what it's worth according to research consensus. You can debate how much the rest of the pipeline is worth, whether someone will buy them out, etc etc...but with regards to Firdlapse, that's what you've got.
I'm not sure about this analysis, I'd like to see your fundamentals that back this up. I am active in this stock and have all of my initial investment back, now playing with the 'houses money'. That being said, the short/medium price outlook has limited short/mid uptick potential from here based on the anticipated Firdapse approvals next month. There are approximately 3000 patients in US/Canada who could be potential candidates for the drug. The anticipated revenue stream from that product would bring the share price only slightly above where it is now, somewhere in the $3.25-$4.00 range. The windfall gains discussed here are more closely based on the anticipation of a buyout, which is VERY dangerous water with a negative P/E balance sheet and 6 employees. For a small speculative straight up gamble, yes you can put it here or on Red 27, but based JUST on the Firdapse approvals we're already nearly at that price target.
NOW, they do also have other drugs in their pipeline that could get to Phase III in Europe in the 2015 timeline and in US/Canada in the 2016 timeline, but again, going long on a microcap biotech with a negative P/E is a risky proposition.
In response to being 'out of your mind', you have to take into account where the entry level was and what level of risk you're willing to take on. This stock has had a history of spike and then bottom drop out, and in today's millisecond trading world where market manipulation by hedges outweighs any individual investor sentiment, I would counter that anyone who has already had a triple on this stock is out of their mind not to take some profit. It does you no good to be right for a while on a stock and not cash in.